Journal Of Clinical Oncology (jco) Podcast

This podcast discusses a phase 2 trial of cabozantinib in men with advanced bone-metastatic prostate cancer, using a novel method to assess bone scan response.

This podcast discusses the results and practical implications of a population-based study that found an increased fracture risk after cystectomy for bladder cancer.

This podcast discusses the current state of knowledge regarding allogeneic transplantation as a treatment modality for advanced systemic mastocytosis.

This study assessed diabetes mellitus risk in long-term Hodgkin lymphoma survivors, and found that a mean pancreatic tail dose of 36 Gy or higher was associated with a significantly increased risk of diabetes mellitus. This finding has important implications in the follow up of long-term Hodgkin lymphoma survivors, and also suggests that in newly diagnosed patients with upper abdominal involvement, the pancreas should be included as in organ-in-risk in the radiotherapy planning.

This podcast reviews the publication of the RESORT manuscript, and puts these results into context with the recently published Ardeshna trial of rituximab vs. observation in follicular lymphoma, concluding that there is no longer a role for rituximab maintenance in low tumor burden follicular lymphoma.

This podcast will use the study reported by Bejar and colleagues to review the role of screening for TET2, DNMT3A, and particularly TP53, mutations in deciding whether to recommend allogeneic hematopoietic cell transplant for patients with myelodysplastic syndromes.

This JCO Podcast provides observations and commentary on the JCO article, "Oncology Fellows' Career Plans, Expectations and Well-Being: Do Oncology Fellows Know What They are Getting In To?" by Tait D. Shanafelt, et al.

This study reports surprisingly good outcomes for children with Ph-like ALL treated on the St. Jude Total Fifteen clinical trial.

Corticosteroids are recommended as part of the WHO analgesic ladder but there is limited evidence for their efficacy for the treatment of pain in cancer patients.

The availability of reconstructive surgeons restricts the use of immediate breast reconstruction, creating unintended inequities even in a system with universal health care coverage.

This podcast describes the rising epidemic of HPV-associated oropharynx cancer, its unique demographic profile and natural history, and comments on new findings from Carole Fakhry et al. regarding patterns of disease recurrence seen in patients enrolled on RTOG 0129 and 0522.

This podcast discusses the report of cardiac monitoring data from the HERA trial, places the findings in context with data from other trials, and considers how the report relates to clinical practice.

This is a review of breast needle biopsy for the diagnosis of breast cancer and how surgeons and geography affect utilization and the resultant impact on quality of care.

FISH genetics, LDH and beta 2-microglobulin can identify a group of newly diagnosed myeloma patients with a two-year survival of only 52% in spite of bortezomib-based therapy.

The current study, reporting on the upfront use of lenalidomide and rituximab in CLL, suggests high response rates and excellent tolerability in younger as well as older patients, albeit with a modest median progression-free survival.

This podcast summarizes the findings of a recent longitudinal functional MRI study examining the effects of breast cancer chemotherapy on multitasking-related brain activation and its relationship to cognitive complaints, and discusses implications and future directions.

This podcast discusses the measures to optimize central-nervous-system-directed therapy in children with acute lymphoblastic leukemia.

This trial supports the use of neoadjuvant capecitabine monotherapy as a potentially more convenient radiosensitizer that does not sacrifice surgical and pathologic outcomes in rectal cancer. However, further study is needed.

This podcast reviews the current role of PET and radiotherapy in PMBL.

This podcast concerns the potential complimentary role played by PET and CT in the assessment of response in patients with Hodgkin lymphoma.